JAGUAR HEALTH, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value
JAGUAR HEALTH, INC. (JAGX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value of $336.43 per share for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-14.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue · last filed 2024-05-14
- JAGUAR HEALTH, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2024-03-31 was $336.43, a 60.59% increase year-over-year.
- JAGUAR HEALTH, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2023-03-31 was $209.49.
- JAGUAR HEALTH, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2022 was $304.57, a 9.52% decline from fiscal 2021.
- JAGUAR HEALTH, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2021 was $336.60, a 5538.19% increase from fiscal 2020.
- JAGUAR HEALTH, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2020 was $5.97, a 91.35% increase from fiscal 2019.
- JAGUAR HEALTH, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2019 was $3.12, a 98.19% decline from fiscal 2018.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|
| 2024-03-31 | $336.43 10-Q · filed 2024-05-14 | ||||
| 2023-12-31 | $273.62 10-Q · filed 2024-05-14 | ||||
| 2023-09-30 | $260.15 10-Q · filed 2023-11-14 | ||||
| 2023-06-30 | $238.60 10-Q · filed 2023-08-14 | ||||
| 2023-03-31 | $209.49 10-Q · filed 2023-05-15 | ||||
| 2022-12-31 | $304.57 10-K · filed 2024-04-01 | ||||
| 2021-12-31 | $336.60 10-K · filed 2023-03-24 | $4.49 10-K · filed 2022-03-11 | |||
| 2020-12-31 | $5.97 10-K · filed 2022-03-11 | $2.00 10-K · filed 2021-03-31 | |||
| 2019-12-31 | $3.12 10-K · filed 2021-03-31 | ||||
| 2018-12-31 | $172.07 10-K · filed 2020-04-03 | ||||
| 2015-12-31 | $0.43 10-K · filed 2017-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |